Skip to main content

Day: April 15, 2025

Castellum, Inc.’s Subsidiary GTMR Adds Professional Services to its Current GSA MAS Contract

Castellum, Inc.’s Subsidiary GTMR Adds Professional Services to its Current GSA MAS ContractCastellum, Inc. (NYSE-American: CTM) announces that its subsidiary Global Technology and Management Resources, Inc. (“GTMR”) has added Special Item Number (“SIN”) 541611 to their existing General Services Administration (“GSA”) Multiple Award Schedule (“MAS”) contract – www.castellum.usVIENNA, Va., April 15, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum” or “CTM”), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its subsidiary Global Technology and Management Resources, Inc. (“GTMR”) has added Special Item Number (“SIN”) 541611 to their existing General Services Administration (“GSA”) Multiple Award Schedule (“MAS”)...

Continue reading

Brazil Potash Advances Autazes Project Construction With Signing of Fauna Rescue Contract

Strategic environmental milestone enables further site preparation for the Autazes Potash Project Contract awarded to experienced Amazonian environmental services firm Ecology Suporte Ambiental e Engenharia with focus on local employmentMANAUS, Brazil, April 15, 2025 (GLOBE NEWSWIRE) — Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE-American: GRO), a mineral exploration and development company with a potash mining project, the Autazes Project, today announced that its subsidiary Potássio do Brasil Ltda. has awarded a contract for fauna rescue services to Ecology Suporte Ambiental e Engenharia (“Ecology Suporte”). This contract represents a critical environmental milestone that advances the Autazes Potash Project toward construction, following the February approval for vegetation...

Continue reading

TRX Gold Reports Second Quarter 2025 Results

Stage Set for Next Phase of Growth TORONTO, April 15, 2025 (GLOBE NEWSWIRE) — TRX Gold Corporation (TSX: TRX) (NYSE American: TRX) (the “Company” or “TRX Gold”) reported its results for the second quarter of 2025 (“Q2 2025”) for the three and six months ended February 28, 2025. Financial results are available on the Company’s website at www.TRXgold.com. Stephen Mullowney, TRX CEO commented: “The past couple of years have set the foundation for continued growth at Buckreef Gold. We have significantly de-risked Buckreef Gold’s operations, building production capacity on-time and on-budget. Our technical team continues to deepen their knowledge of Buckreef Gold’s ore metallurgy and how best to mine the deposit on a cost-effective basis. All of these points come through in our most recent quarter. Our strip campaign over the first...

Continue reading

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Company AnnouncementNet sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,237 million in the first quarter of 2025. Net trade sales were USD 1,829 million in the U.S. and USD 1,409 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop,...

Continue reading

Correction: Mandatory notice of shareholding

Reference is made to IDEX Biometrics ASA’s announcement on 14 April 2025 regarding a notice of large shareholding. By inadvertence, the announcement contained some minor errors in the shareholders name and new number of shares. Please see correct notification below: IDEX Biometrics ASA discloses the following on behalf of a shareholder. Reference is made to the notice by IDEX Biometrics on 11 April 2025 that the Extraordinary General Meeting of the company had, subject to the registration of a share capital reduction, resolved to issue 3,000,000,000 shares in a debt conversion, thereby increasing the number of shares in the company to 3,831,594,232. A close associate of Robert Keith, Charles Street International Ltd., will, subject to the registration of the capital reduction, be allocated 1,000,000,000 shares in the debt conversion and...

Continue reading

EngageLab Powers the Success of a Leading Chinese Cross-Border B2B E-Commerce Platform Amid U.S. Market Surge

SINGAPORE, April 15, 2025 (GLOBE NEWSWIRE) — EngageLab, a world-leading provider of AI-powered omnichannel customer engagement solutions, is proud to support the remarkable growth of a prominent Chinese cross-border B2B e-commerce platform, which recently surged to the #2 spot on the U.S. free iPhone app rankings, second only to ChatGPT. This unprecedented rise highlights the platform’s growing influence in the U.S. market and underscores the importance of cutting-edge email solutions in driving its success. The platform’s rapid ascent comes amidst heightened interest in Chinese cross-border e-commerce, fueled by viral TikTok videos showcasing Chinese factories and their role in global manufacturing. This surge in visibility has led to a dramatic increase in app downloads, with U.S. downloads growing by 940% in just a few days....

Continue reading

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) — Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million) strategic financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) — aimed at expanding Genenta’s pipeline with the advancement of Temferon™ in metastatic Renal Cell Cancer (mRCC) — and the addition of approximately €3.0 million ($3.2 million) raised via at-the-market (ATM) facility, Genenta CEO Pierluigi Paracchi will present at the event, which will be hosted by H.E....

Continue reading

Aurora Mobile’s EngageLab Powers the Success of a Leading Chinese Cross-Border B2B E-Commerce Platform Amid U.S. Market Surge

SHENZHEN, China, April 15, 2025 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that its subsidiary EngageLab, a world-leading provider of AI-powered omnichannel customer engagement solutions, is honored to support the remarkable growth of a prominent Chinese cross-border B2B e-commerce platform, which recently surged to the #2 spot on the U.S. free iPhone app rankings, second only to ChatGPT. This unprecedented rise highlights the platform’s growing influence in the U.S. market and underscores the importance of cutting-edge email solutions in driving its success. The platform’s rapid ascent comes amidst heightened interest in Chinese cross-border e-commerce, fueled...

Continue reading

Vallourec Invitation: Q1 2025 Results Release and Conference Call – Thursday, May 15th, 2025

Q1 2025 Results Release and Conference Call Thursday, May 15th, 2025 Vallourec will publish First Quarter 2025 Results on May 15th, 2025 at 07:30 AM CET. Philippe Guillemot, Chairman of the Board and Chief Executive Officer, and Sascha Bibert, Chief Financial Officer are pleased to invite you to a presentation of the results via conference call and audiocast at 09:30 AM CET. To connect to the audiocast (live and replay), please visit: https://channel.royalcast.com/landingpage/vallourec-en/20250515_1/ To participate in the call, please dial:UK (Standard International Access): +44 (0) 33 0551 0200 US: +1 786 697 3501 FR: +33 (0) 1 70 37 71 66Password: Vallourec The presentation will be available from 09:00 AM CET on Vallourec’s website: https://www.vallourec.com/en/investors About Vallourec Vallourec is a world leader in premium...

Continue reading

Ageas successfully raised EUR 550 million through an accelerated bookbuild offering

Ageas successfully raised EUR 550 million through an accelerated bookbuild offering Ageas SA/NV (“Ageas” or the “Company”) announces that it has successfully raised EUR 550 million by way of an accelerated bookbuild offering of 10,967,099 new ordinary shares in the Company (the “New Shares”), which was announced on 14 April 2025 (the “Share Placement”). The New Shares have been placed at a price of EUR 50.15 per New Share (the “Issue Price”). The Share Placement is intended to partly finance the acquisition of esure1 to establish a top-3 UK personal lines platform, as announced yesterday (the “Transaction”). The Transaction is expected to generate an unlevered return on investment of over 12% for Ageas, translating in a levered return on invested capital (ROIC) in excess of 20%. For more details, please visit the following link: https://ageas.com/en/esure-2025.1...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.